HSA
CRMD icon

HBK Sorce Advisory’s CorMedix CRMD Stock Holding History

HBK Sorce Advisory’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-147,500
Closed -$154K – 642
2022
Q4 		$154K Buy
147,500
+73,750
+100% +$261K ﹤0.01% 671
2022
Q3 		$75K Buy
+73,750
New +$307K 0.01% 502

Other funds holding CRMD

Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

HBK Sorce Advisory's CRMD Position: Q1 2023 in Review

HBK Sorce Advisory sold out of CorMedix (CRMD) in Q1 2023, closing a stake of 147,500 shares — an estimated $154K sold.

HBK Sorce Advisory first reported a position in CRMD in Q3 2022 and held it in 2 quarters. The position peaked at $154K in Q4 2022. 65 funds tracked by Wall St. Rank hold CRMD as of Q1 2023.

  • HBK Sorce Advisory reported no remaining CorMedix position as of Q1 2023 after selling out during the quarter.
  • HBK Sorce Advisory sold 147,500 CorMedix shares in Q1 2023, an estimated $154K.
  • HBK Sorce Advisory first reported a position in CorMedix in Q3 2022 and held it in 2 quarters.
  • HBK Sorce Advisory's CorMedix position peaked at $154K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held CorMedix as of Q1 2023.

Based on HBK Sorce Advisory's 13F filing for Q1 2023, filed 15 May 2023.